Fmr LLC Has $1.20 Million Stock Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT)

FMR LLC lifted its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 102.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 233,566 shares of the company's stock after buying an additional 117,965 shares during the quarter. FMR LLC owned about 0.16% of Adaptive Biotechnologies worth $1,196,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Millennium Management LLC grew its stake in shares of Adaptive Biotechnologies by 1,008.3% during the 2nd quarter. Millennium Management LLC now owns 9,262,341 shares of the company's stock worth $33,530,000 after acquiring an additional 8,426,580 shares in the last quarter. Rubric Capital Management LP grew its holdings in shares of Adaptive Biotechnologies by 33.3% in the 2nd quarter. Rubric Capital Management LP now owns 14,000,000 shares of the company's stock valued at $50,680,000 after acquiring an additional 3,500,000 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Adaptive Biotechnologies by 50.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,912,027 shares of the company's stock valued at $14,162,000 after acquiring an additional 1,319,709 shares during the last quarter. ARK Investment Management LLC raised its holdings in Adaptive Biotechnologies by 8.1% during the second quarter. ARK Investment Management LLC now owns 11,412,000 shares of the company's stock worth $41,311,000 after acquiring an additional 850,704 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in Adaptive Biotechnologies by 12.1% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,733,884 shares of the company's stock valued at $39,597,000 after purchasing an additional 834,253 shares in the last quarter. 99.17% of the stock is owned by institutional investors.

Adaptive Biotechnologies Trading Down 3.8 %

NASDAQ ADPT traded down $0.26 during trading on Tuesday, reaching $6.52. The company's stock had a trading volume of 1,741,650 shares, compared to its average volume of 1,411,985. Adaptive Biotechnologies Co. has a 12 month low of $2.28 and a 12 month high of $7.07. The firm has a 50 day moving average price of $5.40 and a 200 day moving average price of $4.61. The firm has a market capitalization of $962.22 million, a price-to-earnings ratio of -4.84 and a beta of 1.49.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ADPT shares. BTIG Research raised their target price on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, October 2nd. Piper Sandler lifted their price target on Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an "overweight" rating in a report on Monday, November 11th.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.